Citalopram and metacognitive therapy for depressive symptoms and cognitive emotion regulation in patients with major depressive disorder: A randomized controlled trial
Volume 10, Issue 1, January 2020, Pages 1-6
. Gholam Reza Kheirabadi, . Zahra Yousefian, . Fatemeh Zargar, . Mahboobe Bahrami, . Mohammad R Maracy
Abstract BACKGROUND: Metacognitive therapy (MCT) is a new psychotherapy for depression. This
study was conducted to compare the effectiveness of citalopram and MCT on major depressive
disorders (MDDs).
MATERIALS AND METHODS: A total of 36 patients with MDD were randomly assigned into three
groups of citalopram (n = 12), MCT (n = 16), and control (n = 8). MCT group received ten sessions
of metacognition therapy. Citalopram group received 20–40 mg citalopram, and the control group
did not receive any interventions. Outcomes were measured using the Beck Depression Inventory‑II,
Metacognition Questionnaire‑30, and Cognitive‑Emotion Regulation (CER) Questionnaire. Data were
analyzed with ANCOVA using SPSS version 18.
RESULTS: Depression score reduction was significant in both citalopram and metacognitive
groups (P < 0.05). However, there was only a statistically significant difference between MCT and
control group in CER and metacognition.
CONCLUSION: MCT and citalopram both are effective in symptom reduction in MDD. Furthermore,
MCT could lead to more improvement in metacognition, depression symptoms, and CER than
citalopram, when treating MDDs.
